Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: Results from the ROCKET AF trial

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1873-1880

  Piccini, Jonathan P ^a   Garg, Jyotsna ^a   Patel, Manesh R ^a   Lokhnygina, Yuliya ^a   Goodman, Shaun G ^b   Becker, Richard C ^c   Berkowitz, Scott D ^d   Breithardt, Günter ^e   Hacke, Werner ^f   Halperin, Jonathan L ^g   Hankey, Graeme J ^h   Nessel, Christopher C ⁱ   Mahaffey, Kenneth W ^j   Singer, Daniel E ^k   Califf, Robert M ^l   Fox, Keith A A ^m  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF CINCINNATI   (United States)

^d BAYER CORPORATION   (United States)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g MOUNT SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Atrial fibrillation; Bleeding; Factor Xa inhibitor

Indexed keywords

FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CRYOPRECIPITATE; DOUBLE BLIND PROCEDURE; EMBOLISM; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; BLOOD TRANSFUSION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEMORRHAGE; HOSPITALIZATION; PLASMA; STATISTICS AND NUMERICAL DATA; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ATRIAL FIBRILLATION; BLOOD TRANSFUSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MORPHOLINES; PLASMA; STROKE; THIOPHENES; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84904129516     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu083     Document Type: Article

References (11)

1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891
2. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013;34:489-498
3. Patel M. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am Heart J 2010;2159: 2340-2347
4. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3: 692-694
5. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Vesely SK, Schulman S, Kovacs MJ, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial. Ann Intern Med 2009;150:293-300
6. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-Associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006;67: 1272-1274
7. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480
8. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124: 1573-1579
9. Schulman S. Clinical practice. Care of patients receiving long-Term anticoagulant therapy. N Engl J Med 2003;349:675-683
10. Dentali F, Ageno W, Crowther M. Treatment of coumarin-Associated coagulopathy: A systematic review and proposed treatment algorithms. J Thromb Haemost 2006;4: 1853-1863
11. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128: 2325-2332.